Latest Gilead Sciences Stories
Doctor Evidence, LLC has developed a comprehensive database of clinical evidence in Hepatitis C (HCV) to address the evolving needs of healthcare stakeholders. Santa
FLINT, Mich., July 28, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced today that it has been selected as a provider of Zydelig(®) tablets.
MELBOURNE, Australia, July 24, 2014 /PRNewswire/ -- Announced at the 20th International AIDS Conference in Melbourne, the agreement seeks to increase access
CALGARY, July 23, 2014 /PRNewswire/ - Zenith Epigenetics Corp.
Mazzo, Melmed and Meyers Elected to Board La Jolla, Calif.
Among heterosexual African couples in which the male was HIV positive and the female was not, receipt of antiretroviral pre-exposure preventive (PrEP) therapy did not result in significant differences in pregnancy incidence, birth outcomes, and infant growth compared to females who received placebo.
SOUTH SAN FRANCISCO, Calif., June 23, 2014 /PRNewswire/ -- Tobira Therapeutics, a clinical-stage biopharmaceutical company advancing cenicriviroc (CVC) in liver disease and HIV, announced today
A new combination therapy could cut treatment time for hepatitis C to just four weeks, but quicker recovery comes with a steep price, as the new medication is said to cost roughly $1,000 per pill.
HAYWARD, Calif., June 13, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare
- A poem in which the author retracts something said in an earlier poem.